Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. Tropazone™ utilizes patented Lyphazome™ technology. This delivery system prolongs product activity while enhancing penetration and hydration of the skin. Tropazone™ is patent protected, and two additional patents are pending. Tropazone™ will be promoted by ECR’s 55 person field force beginning February 2010.

“We are pleased to introduce another unique prescription branded product to the market”

“We are pleased to introduce another unique prescription branded product to the market”, said David Seltzer, President and CEO of Hi-Tech Pharmacal. “Tropazone™ lotion provides physicians and their patients with an effective delivery system to treat dermatitis.”